HGWM
CYTK icon

Harvest Group Wealth Management’s Cytokinetics CYTK Stock Holding History

Harvest Group Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14
Closed – – 191
2020
Q4 		$0 Buy
+14
New +$256 ﹤0.01% 687

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Harvest Group Wealth Management's CYTK Position: Q1 2021 in Review

Harvest Group Wealth Management sold out of Cytokinetics (CYTK) in Q1 2021, closing a stake of 14 shares.

Harvest Group Wealth Management first reported a position in CYTK in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 192 funds tracked by Wall St. Rank hold CYTK as of Q1 2021.

  • Harvest Group Wealth Management reported no remaining Cytokinetics position as of Q1 2021 after selling out during the quarter.
  • Harvest Group Wealth Management sold 14 Cytokinetics shares in Q1 2021.
  • Harvest Group Wealth Management first reported a position in Cytokinetics in Q4 2020 and held it in 1 quarter.
  • Harvest Group Wealth Management's Cytokinetics position peaked at $0 in Q4 2020.
  • 192 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2021.

Based on Harvest Group Wealth Management's 13F filing for Q1 2021, filed 4 May 2021.